Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Senior Director, Commercial Regulatory Affairs, is responsible for the development and execution of the post-approval regulatory strategy, post-marketing commitments, post-marketing development and maintenance, regulatory operations and filings-related activities including regulatory submissions, regulatory compliance, regulatory advice and counseling, advertising and promotion reviews, and marketing application registration updates in close collaboration with Mitsubishi Tanabe Pharma Corporation, Inc. (MTPC) and all subsidiaries. Regulatory activities pertain primarily to marketed products in US and Canada.   In addition, the Senior Director, Commercial Regulatory Affairs, in collaboration with Head, Regulatory Affairs and CMC-RA, will review and assess all commercial communications including advertising and promotional information, materials, and activities to ensure consistency with product labeling and with all applicable regulations. The Senior Director, Commercial Regulatory Affairs will stay abreast of changes in the global/U.S./Canadian regulatory framework, analyze proposed legislation/guidance that could impact the business and its products, and in conjunction with the Regulatory Affairs, Regulatory Strategists, recommend appropriate actions to senior leadership.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Accountant supports Mitsubishi Tanabe Pharma America from a payables and accounting standpoint.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) based in Toronto, is a wholly owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), which touts a storied reputation more than 300 years in the making. Our parent company, Mitsubishi Tanabe Pharma Corporation (MTPC) - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTP-C’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in Canadian markets. The company handles sales, marketing, market access, and business development functions. MTP-C is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness and currently seeking motivated professionals who share our vision of scientific excellence, innovation, and unwavering dedication to improving the lives of patients.   The Director Pricing, Market Access & Government Affairs will assume responsibility for leading the development and execution of strategies that ensure optimal & sustainable pricing, access and reimbursement through public and private reimbursement systems for the Mitsubishi Tanabe Pharma Canada (MTP-CA) portfolio; lead the preparation of Common Drug Review, Institut National en Santé et Services Sociaux (INESSS) and private payer submissions; develop & manage payer relationships; lead & implement the negotiation of unique, creative, and profitable payer-specific product listing agreements; represent MTP-CA at trade associations tables to help influence the creation of policies that  foster a sustainable market access environment in line with MTP-CA’s core assets in specialty neurology &rare diseases.   The incumbent will also establish and anchor the position of the business as a leader and essential partner in the healthcare arena, demonstrating the value of the information and analysis that the business makes available. with the ultimate goal of improving health outcomes: to do so, the incumbent will build close, constructive & sustainable relationships with key health stakeholders, including government officials, members of Parliament and assemblies, legislative bodies, privacy commissioners, professional associations representing doctors and pharmacists and other non-governmental organizations s, patient associations, and research and academic institutions. By creating these alliances, the incumbent aims to advance MTP-CA’s mission and to mitigate any possible threat.   A critical success factor of this role will be demonstrating specific competencies through a sound understanding of a complex pricing & reimbursement environment, ability to use a critical thinking approach to influence market access external third-party stakeholders develop and/or implement unique policies in a fast pace paradigm shifting landscape. Demonstrate sound ability in utilizing clinical knowledge, health economic and outcomes research, marketing resources, and leveraging and negotiating the value proposition which may include innovative contract strategy and rebating.  Demonstrate strong strategic mindset, negotiating, influential and planning skills as well as financial stewardship for the company.  Collaborate proactively with Medical Affairs to generate RWE that will lead to improved patient access for in line & pipeline assets. Contribute to high-level, cross-functional and cross-country decisions working with sales & marketing, finance, advocacy, contracting and other internal departments, locally & abroad for in line & pipeline drug products.    The Director Pricing, Market Access & Government Affairs will ensure continuous access of the portfolio in order to guarantee future revenue growth & sustainability.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account Specialist (NAS) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for ALS and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Director, Translational Medicine (TM), will be primarily responsible for creating plans for early clinical development and implementing translational plans that are aligned with company’s disease and pathway strategies. The successful candidate will be responsible for shaping the strategic vision for programs and in creating and implementing experimental medicine studies. This role will partner with translational research to engage in external interactions with academic institutions having strong capabilities in translational studies and with external scientific experts.   Reporting into the Senior Director of the Translational Medicine (TM) group, the Director, TM will lead clinical and scientific aspects of translational studies from Phase 0 through Proof-of-Concept studies. In this role, the Director, TM, will contribute to accelerating the company’s pipeline from portfolio entry to Proof-of-Concept (PoC). The Director, TM, should have expertise in one or more of the TM areas: early-stage clinical development, biomarker development, precision medicine, and disease biology research.   The Translational Medicine group of Early Clinical Development serves as a pivotal bridge between Discovery/Translational Research and the later phase Clinical Development group. It provides the necessary scientific and clinical expertise to advance an industry-leading pipeline of novel mechanism small molecules and biologic agents to address unmet need in immunology, neurology, and other rare diseases. This position will play a ‘dual role’, contributing both scientific and early clinical development expertise.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    As a senior member of Medical Science, the Senior Director, Medical Science will lead the early- to late-stage development team(s) in designing, planning, implementing and executing clinical development plans and programs in accordance with company processes, SOPs, and FDA/ICH guidelines and regulations. The incumbent will lead the successful delivery of late-stage clinical milestones such as EOP2, NDA and MAA for the company, drawing on expertise in clinical and regulatory strategy and requirements, both local and international, related to the clinical medicine and drug development processes. He/she will lead large global, multidisciplinary teams, mentoring and motivating individual team members, to meet overall corporate objectives leading to submission for world-wide marketing applications. Therapeutic areas may vary, and the pipeline candidates may be small molecules or biologics covering various therapeutic areas involving complex indications including rare disease/orphan conditions.   The Senior Director, Medical Science will be responsible for clinical development strategy, clinical program oversight, and oversight of clinical interactions with regulatory agencies. This will involve leading the design, implementation, monitoring, analysis, and reporting of clinical studies supporting his/her program. He/she will also lead/participate in developing the long-range strategic plans and commercial planning.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Director, Clinical Science (I&I) will lead the early- to late-stage development team(s) in designing, planning, implementing and executing clinical development plans and programs in accordance with company processes, SOPs, and FDA/ICH guidelines and regulations. As a senior clinical development team member, the incumbent will lead the successful delivery of milestones for assigned project(s), such as IND, EOP2, NDA and MAA for the company, drawing on expertise in clinical and regulatory strategy and requirements, both local and international, related to the clinical medicine and drug development processes. The Director, I&I will lead multidisciplinary teams, mentoring and motivating individual team members to meet overall corporate objectives. Specific targeted conditions within the I&I therapeutic area may vary based on priorities of the current pipeline; however, experience with rare diseases associated with immunology, inflammation, and/or dermatology disorders is desired.   Overall responsibilities will include clinical development strategy, clinical program oversight, and oversight of clinical interactions with regulatory agencies within the I&I therapeutic area. This may include leading the design, implementation, monitoring, analysis, and reporting of clinical studies for I&I programs. The Director, Clinical Science (I&I) will also lead/participate in developing the long-range strategic plans and commercial planning of I&I indications.

Soutwest - Dallas, TX or Houston, TX   Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Regional Business Director - Parkinson's Disease (RBD-PD) will be responsible for building and leading a team of Neurology Account (PD) Specialists, launching approved products, creating, and executing strategies, developing people, managing performance, and driving results for Mitsubishi Tanabe Pharmaceutical’s approved products.  This experienced sales leader will draw upon strong business acumen, in-depth knowledge of the specialty pharmaceutical market and significant launch experience. The incumbent will rely on a highly collaborative, customer-focused approach to achieve goals and objectives.   The RBD-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern and be responsible for the management of sales, pre-launch activities, strategic business planning and implementation of approved products for the assigned region. The RBD-PD will build and direct a team of Neurology Account (PD) Specialists in the acquisition, expansion, and retention of targeted business within the assigned geographic area. In the execution of all duties, the RBD-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations

Central - Chicago, IL or Indianapolis, IN   Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Regional Business Director - Parkinson's Disease (RBD-PD) will be responsible for building and leading a team of Neurology Account (PD) Specialists, launching approved products, creating, and executing strategies, developing people, managing performance, and driving results for Mitsubishi Tanabe Pharmaceutical’s approved products.  This experienced sales leader will draw upon strong business acumen, in-depth knowledge of the specialty pharmaceutical market and significant launch experience. The incumbent will rely on a highly collaborative, customer-focused approach to achieve goals and objectives.   The RBD-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern and be responsible for the management of sales, pre-launch activities, strategic business planning and implementation of approved products for the assigned region. The RBD-PD will build and direct a team of Neurology Account (PD) Specialists in the acquisition, expansion, and retention of targeted business within the assigned geographic area. In the execution of all duties, the RBD-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations

Mid Atlantic - Atlanta, GA   Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Regional Business Director - Parkinson's Disease (RBD-PD) will be responsible for building and leading a team of Neurology Account (PD) Specialists, launching approved products, creating, and executing strategies, developing people, managing performance, and driving results for Mitsubishi Tanabe Pharmaceutical’s approved products.  This experienced sales leader will draw upon strong business acumen, in-depth knowledge of the specialty pharmaceutical market and significant launch experience. The incumbent will rely on a highly collaborative, customer-focused approach to achieve goals and objectives.   The RBD-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern and be responsible for the management of sales, pre-launch activities, strategic business planning and implementation of approved products for the assigned region. The RBD-PD will build and direct a team of Neurology Account (PD) Specialists in the acquisition, expansion, and retention of targeted business within the assigned geographic area. In the execution of all duties, the RBD-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations

Mountain West - Denver, CO or Phoenix, AZ   Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Regional Business Director - Parkinson's Disease (RBD-PD) will be responsible for building and leading a team of Neurology Account (PD) Specialists, launching approved products, creating, and executing strategies, developing people, managing performance, and driving results for Mitsubishi Tanabe Pharmaceutical’s approved products.  This experienced sales leader will draw upon strong business acumen, in-depth knowledge of the specialty pharmaceutical market and significant launch experience. The incumbent will rely on a highly collaborative, customer-focused approach to achieve goals and objectives.   The RBD-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern and be responsible for the management of sales, pre-launch activities, strategic business planning and implementation of approved products for the assigned region. The RBD-PD will build and direct a team of Neurology Account (PD) Specialists in the acquisition, expansion, and retention of targeted business within the assigned geographic area. In the execution of all duties, the RBD-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations

Northeast - Philadelphia, PA; New Jersey; or New York    Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Regional Business Director - Parkinson's Disease (RBD-PD) will be responsible for building and leading a team of Neurology Account (PD) Specialists, launching approved products, creating, and executing strategies, developing people, managing performance, and driving results for Mitsubishi Tanabe Pharmaceutical’s approved products.  This experienced sales leader will draw upon strong business acumen, in-depth knowledge of the specialty pharmaceutical market and significant launch experience. The incumbent will rely on a highly collaborative, customer-focused approach to achieve goals and objectives.   The RBD-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern and be responsible for the management of sales, pre-launch activities, strategic business planning and implementation of approved products for the assigned region. The RBD-PD will build and direct a team of Neurology Account (PD) Specialists in the acquisition, expansion, and retention of targeted business within the assigned geographic area. In the execution of all duties, the RBD-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Senior Manager will support signal detection activities and medical analyses to support evaluation and characterization of safety topics for products working closely with Drug Safety Global Safety Team (GST) Chair (Medical Director). The Manager, MSE will perform signal management process activities for assigned products, including combination products (drug and device) including signal tracking, safety data analysis, and presenting in the GST governance meetings. Incumbent will perform the review of worldwide medical/scientific literature to identify information applicable for inclusion in aggregate reports and for potential safety signals, and author safety aggregate reports as needed. The Manager, MSE performs medical analyses for risk characterization to develop Risk Management Plans (RMPs). The Manager will also draft responses for regulatory authority inquires on aggregate reports and author applicable information and data for marketing applications [New Drug Applications (NDA), New Drug Submission (NDS)], Amendments, Supplements, Safety Reports, and general correspondence for all assigned.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Medical Director is responsible for leading Mitsubishi Tanabe Pharma America (MTPA) global product and/or combination product level safety analysis and strategic medical safety management throughout the product lifecycle within the Global Drug Safety and Evaluation Center (GDSEC). Incumbent implements corporate policies to ensure the safety of the product in global product portfolio. The Medical Director is accountable for providing medical input to the assessment of the safety profile for each global product and for appropriate and timely regulatory reporting of safety issues.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Medical Science Liaison provides a vital role to the organization by bridging internal strategy with external medical insights. Through interactions with the healthcare community, the Medical Science Liaison supports disease awareness activities, participates in scientific exchange, and obtains valuable information regarding unmet medical needs and current treatment paradigms to help guide executive decisions. As part of an emerging US and global organization, the Medical ScienceLiaison  will also make significant contributions to processes, procedures, and best practices within the developing organization, serve as a medical resource to healthcare providers, clinical investigators and clinical study sites, and healthcare decision makers regarding the organization’s investigational and marketed products, and support product commercialization. The Medical Science Liaison will report directly to the Field Medical Director, Medical Affairs.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.  The Senior Manager, HR is accountable for building and maintaining strong relationships with the clients they support. Partnering with other members of the HR team and other key internal partners, the HRBP Senior Manager will leverage knowledge and best practices to provide guidance and counsel to management team, supporting the building and maintenance of a skilled and motivated workforce capable of and committed to, delivering their business strategy. The Senior Manager, HR acts as an advisor to assigned management teams by providing advice and guidance on sensitive and often complex HR issues, in the areas of compensation, performance management, learning & development, recruitment, job evaluation, change management and employee issue resolution. The Senior Manager, HR also serves as a direct liaison between the Executive Director and the Centers of Excellence (e.g., Talent Development, Talent Acquisition, Payroll and Benefits, etc.) interfacing with them frequently, communicating business priorities and ensure delivery of those HR products and services to the business.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Manager, Sales Operations is responsible for managing execution of various processes that support the commercial infrastructure on sales, reimbursement, and other teams.  This role will be directly responsible for sales operations activities for Radicava, Exservan, and other future products.  This position offers an extraordinary opportunity for individuals interested in helping to grow a US company with immediate opportunities in the Orphan Drug and Specialty Markets, therapeutic areas with high unmet needs, while working with a cross-functional team rich in exceptional talent.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The IT Helpdesk, Support Technician will provide day-to-day local/remote desktop support, receive inbound calls, answer questions, troubleshoot and document steps performed to resolve challenges with hardware, software, and application issues in a ticketing system.The incumbent will also facilitate customer request resolution, and work in a team environment to ensure operational consistency within the IT Department.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Manager, Financial Planning & Analysis (FP&A) serves as a financial liaison for multiple business partners and functions. The incumbent provides business partners with financial reporting and analysis that are used for strategic and tactical decision-making. The Manager, FP&A works with various levels of management to develop, interpret and implement financial and accounting concepts or techniques related to strategic planning, budgeting, and forecasting to drive business results. The role is also responsible to support systems, data management and business analysis to support tactical and strategic insight to management.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Manager, Business Operations and Transparency Reporting is responsible for (1) supporting transparency and reporting activities and (2) providing operational support to facilitate systems, workflows, and processes meeting transparency reporting and compliance requirements.  This role will also lead key compliance-driven operational initiatives, projects, and activities for supporting the field operations. This person will liaise between internal functions and external service providers to ensure operational success of business operations and transparency initiatives.